L’Oreal USA, Inc. faces multiple class action complaints in US federal courts regarding its marketing of benzoyl peroxide (BPO) acne treatment drug products alleging containing benzene.
“Before being sold to the public, the [BPO] Products must be made in conformity with current good manufacturing practices and must conform to quality, safety, and purity specifications. Defendant’s BPO Products did not,” alleges plaintiff Jennifer Snow in her 8 March
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?